



wherein n is an integer from 4 to 13 and R is H or  $\text{CO}_2\text{R}'$  wherein  $\text{R}'$  is  $\text{C}_{8-22}$  saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen;

c) 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2)



wherein n is an integer from 0 -10 and  $\text{R} = \text{H}$  or  $\text{CO}_2\text{R}''$  wherein  $\text{R}''$  is  $\text{C}_{8-22}$  saturated, unsaturated or hydroxylated alkyl, and wherein at least one group R is not hydrogen;

d) 5 to 50% of one or more compounds selected from the group consisting of triglyceride macrogol glycerol esters, partial glycerides of fatty acids and magrogol esters of fatty acids in which the average quantity of reacted ethylene oxide in the synthesis of these substances ranges between 50 to 150 mols and concurrently the ratio between components b) and d) is from 0.1:1 to 10:1;

wherein the above percentages are selected to total 100%;

and wherein upon dilution with water 1:1 by volume the viscosity of the formulation increases by at least 5 times in comparison to the undiluted composition.

B<sup>2</sup> 25. (Amended) A formulation as claimed in claim 2, wherein component a) is selected from cyclosporins cyclosporin A, cyclosporin D or cyclosporin G, wherein the ratio of components a : c + e is 1.001 : 1 to 1.5 : 1.

B<sup>3</sup> 27. (Amended) A formulation as claimed in claim 2, wherein component a) is selected from taxanes docataxel or paclitaxel, wherein the ratio of components a : c + e is 0.001 : 1 to 1.5 : 1.

B<sup>4</sup> 29. (Amended) A formulation as claimed in claim 2, wherein component a) includes at least one compound selected from the group comprising cyclosporins and further at least one compound selected from the group comprising taxanes.